Search Results
May 14, 2026, 13:00 ET Children's Hospital of Philadelphia Selects Jesse A. Taylor, MD, as Surgeon-in-Chief
Joseph W. St. Geme III, MD, Physician-in-Chief and President of the CHOP Practice Association. "As we recognize Dr. Adzick's contributions to CHOP, we are also fortunate
More news about: Children's Hospital of Philadelphia
May 14, 2026, 12:30 ET Cboe Global Markets Announces 2026 Annual Meeting Results
received a majority of votes cast. The board members elected to serve one-year terms expiring in 2027 are:William M. Farrow, IIICraig S. DonohueEdward J. FitzpatrickIvan K. FongJanet P. FroetscherJill R. GoodmanErin A. MansfieldCecilia
More news about: Cboe Global Markets, Inc.
May 14, 2026, 11:59 ET PINS INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Pinterest (PINS) Investors of Securities Class Action Deadline on May 29, 2026
reallocating resources to AI-focused roles and teams that drive AI adoption and execution, (ii) prioritizing AI powered products and capabilities, and (iii) accelerating the transformation of its sales and go-to-market approach."On this news, Pinterest's stock price fell $2.49 per share, or 9.61%,
More news about: Faruqi & Faruqi, LLP
May 14, 2026, 10:45 ET VisionWave Seeks to Operationalize Neuro-Logic IP Across Solar Drone Platforms
the contemplated terms or at all; (ii) technology development, integration and proof-of-concept risks associated with xCalibre™ and other platforms; (iii) the risk that provisional patent applications will not result in issued claims of commercial value or that any issued patents may not be enforceable;
More news about: USA News Group
May 14, 2026, 10:19 ET IMMP INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026
laws by making false and/or misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its TACTI-004 Phase III clinical trial study. Particularly following positive top-line results from Immutep's prior TACTI-002 and INSIGHT-003 studies. Further, defendants announced
More news about: Faruqi & Faruqi, LLP
May 14, 2026, 09:07 ET New Analysis in JNCCN Offers Evidence for Effective Use of Medication to Combat Fatigue in People with Cancer
strategies take effect."Results were based on nine different double-blind, individually randomized, parallel-group, placebo-controlled, phase II/III trials evaluating either MPH or d-MPH in adults with advanced cancer or actively receiving cancer-directed treatment. There were 823 total patients included.
More news about: National Comprehensive Cancer Network
May 14, 2026, 08:30 ET XTI Aerospace Reports First Quarter 2026 Results
is defined as EBITDA adjusted for certain items including, (i) non-cash stock-based compensation expense; (ii) severance and restructuring charges; (iii) change in the fair value of warrant liability; and (iv) selected charges that are unusual or non-recurring.The Company believes that EBITDA and
More news about: XTI Aerospace, Inc.
May 14, 2026, 08:17 ET YY Group (NASDAQ: YYGH) Joins Singapore Hotel Association as Associate Member
the hospitality market across Southeast Asia, Hong Kong, and other markets in which the Company operates, (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, (vi) our ability to successfully
More news about: YY Group Holding Limited
May 14, 2026, 07:55 ET Contango Announces Results for the Quarter Ended March 31, 2026
patented mining claims located in the Willow Mining District about 75 miles north of Anchorage, Alaska, from the underlying owner, Alaska Hardrock Inc., (iii) mineral rights to approximately 145,000 acres of State of Alaska mining claims, and (iv) mineral rights to approximately 11,700 acres of State of Alaska
More news about: Contango Silver & Gold Inc.
May 14, 2026, 07:27 ET Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The
More news about: Cardiol Therapeutics Inc.
May 14, 2026, 07:10 ET REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
positive safety outcomes and is being evaluated in the Phase I/II/III AFFINITY DUCHENNE® trial in ambulatory patients aged 1+.REGENXBIO today announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202, including primary endpoint (n=30
More news about: REGENXBIO Inc.
May 14, 2026, 07:05 ET Cypherpunk Technologies Reports First Quarter 2026 Financial Results
sirexatamab; (ii) our estimates regarding our capital requirements and our ability to raise additional financing to support continued development; (iii) the success of other competing therapies that may become available; (iv) the manufacturing capacity for sirexatmab; and (v) our ability to maintain
More news about: Cypherpunk Technologies Inc.
May 14, 2026, 07:05 ET Cypherpunk Technologies Reports First Quarter 2026 Financial Results
sirexatamab; (ii) our estimates regarding our capital requirements and our ability to raise additional financing to support continued development; (iii) the success of other competing therapies that may become available; (iv) the manufacturing capacity for sirexatmab; and (v) our ability to maintain
More news about: Cypherpunk Technologies Inc.
May 14, 2026, 07:00 ET REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) announced positive topline and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY DUCHENNE® trial of RGX-202, a potential best-in-class gene therapy for Duchenne Muscular Dystrophy. The trial met
More news about: REGENXBIO Inc.
May 14, 2026, 07:00 ET Quarterhill Reports First Quarter 2026 Financial Results
MeasuresWe use the non-IFRS financial measure "Adjusted EBITDA" to mean net loss adjusted for (i) income taxes, (ii) finance expense or income; (iii) amortization and impairment of intangibles; (iv) other charges and other one-time items; (v) depreciation of right-of-use assets and property, plant
More news about: Quarterhill Inc.
May 14, 2026, 07:00 ET URBAN ONE, INC. REPORTS FIRST QUARTER 2026 RESULTS
Alfred C. Liggins, III, Urban One's CEO and President stated, "First quarter revenue was soft across all divisions, with TV down 18.5%, Digital down 33.5%, Radio down 6.4%
More news about: Urban One, Inc.
May 14, 2026, 06:30 ET CGI named a Leader in ISG Provider Lens® Global Capability Center (GCC) Services 2026 report
(GIB.A) and the NYSE (GIB). Learn more at cgi.com.About Information Services Group (ISG)Information Services Group (ISG) (Nasdaq: III) is a leading global AI-centered technology research and advisory firm. Founded in 2006, ISG is a trusted partner to more than 900 clients, including
More news about: CGI Inc.
May 14, 2026, 06:30 ET VIZSLA SILVER APPOINTS FORMER SENIOR MEXICAN GOVERNMENT MINING OFFICIAL AS VICE PRESIDENT, GOVERNMENT RELATIONS
Spain, one of Europe's leading law firms. Mr. Gómez Olmos holds a Law Degree from La Salle University in Mexico City and a second Law Degree from Carlos III University of Madrid. He holds a Master's degree in Legal Practice and Business Advice from the Higher Institute of Law and Economics in Madrid and is
More news about: Vizsla Silver Corp.
May 14, 2026, 05:43 ET "I'm On Bottle Number 4 And Can Honestly Say That My Skin Is Glowing." Top 5 ActivatedYou Essential Skin Food Reviews 2026
apparel brand Qeep Up, ActivatedYou founder, and actor—best known for her roles in Nikita, Designated Survivor, and Mission: Impossible III — Maggie Q uses her name to advocate for those in need. Maggie's personal health struggles led her to conduct extensive research in nutrition and inspired
More news about: ActivatedYou
May 13, 2026, 22:09 ET METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals
complete a Phase III clinical trial. MTS-004 is the first and only PBA (pseudobulbar affect) drug in China to have completed clinical trials, and is expected to fill the gap in PBA drug treatment in China. The MTS-004 program took 38 months from project initiation to completion of the Phase III clinical trial.
More news about: METiS TechBio
May 13, 2026, 21:41 ET 晶泰生態賦能項目劑泰科技成功IPO，產業稀缺生態平台全面邁入價值兌現期
倍。在商業化策略上，劑泰科技采用「平台合作+產品合作」的雙輪驅動商業模式，形成「技術迭代－商業應用－真實數據反饋」的再循環協同生態。劑泰科技已與全球超 30 家制藥及生物技術伙伴建立合作，成立 6 年，已布局超 10 款管線產品。其中，MTS-004 是中國首款完成 III 期臨床的 AI 賦能制劑新藥，也是國內目前唯一一款完成臨床試驗的PBA（假性延髓情緒失控）藥物，有望填補巨大的臨床治療空白，從立項到完成 III 期臨床僅用 38 個月；MTS-105 有望成為全球首款體內mRNA編碼TCE實體瘤療法，用於治療肝癌及其他伴有肝轉移的晚期實體瘤，已進入研究者發起臨床（IIT）階段並獲美國 FDA 孤兒藥資格認定。劑泰科技的平台實力已獲得臨床試驗與授權合作的雙重產業驗證。其單一靶點平台合作金額可達
More news about: 晶泰科技
May 13, 2026, 20:00 ET Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease
which will help accelerate the global clinical development and market launch of AR1001, an innovative oral therapy for AD. If the results of the Phase III clinical trial further validate its efficacy and safety, AR1001 has the potential to become a groundbreaking treatment for AD, offering patients a new
More news about: Fosun Pharma
May 13, 2026, 16:30 ET Century Casinos Announces Appointment to Top Leadership Role in the United States
includes the Century Casinos & Hotels in Cape Girardeau and Caruthersville, Missouri, and in Cripple Creek and Central City, Colorado; (iii) US West includes the Nugget Casino Resort in Reno-Sparks, Nevada; (iv) Canada includes Century Casino & Hotel in Edmonton,
More news about: Century Casinos, Inc.
May 13, 2026, 16:05 ET Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook
replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditures for such replacements or for new capital expenditure requirements; (iii) Adjusted EBITDA also does not reflect changes in, or cash requirements for, our working capital needs or the potentially dilutive impact of stock-based
More news about: Shoulder Innovations
May 13, 2026, 16:05 ET Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
release; (ii) Talphera's developmental product candidates may not be beneficial to patients or healthcare providers or be successfully commercialized; (iii) risks relating to Talphera's ability to obtain regulatory approvals for its developmental product candidates; (iv) risks related to the ability of Talphera
More news about: Talphera, Inc.